Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
From advanced diagnosis to advanced resection in early neoplastic colorectal lesions: Never-ending and trending topics in the 2020s.
Auriemma F, Sferrazza S, Bianchetti M, Savarese MF, Lamonaca L, Paduano D, Piazza N, Giuffrida E, Mete LS, Tucci A, Milluzzo SM, Iannelli C, Repici A, Mangiavillano B. Auriemma F, et al. Among authors: giuffrida e. World J Gastrointest Surg. 2022 Jul 27;14(7):632-655. doi: 10.4240/wjgs.v14.i7.632. World J Gastrointest Surg. 2022. PMID: 36158280 Free PMC article. Review.
Agreement between patients and physicians on scores of inflammatory bowel disease activity and burden assessed on a telemonitoring platform.
Mangia M, Giuffrida E, Figini V, Colombo A, Carli E, Lavagna A, Mendolaro M, Morello E, Cosimato M, Rocca R, Pagana G, Daperno M. Mangia M, et al. Among authors: giuffrida e. Scand J Gastroenterol. 2023 Mar;58(3):240-247. doi: 10.1080/00365521.2022.2124538. Epub 2022 Sep 23. Scand J Gastroenterol. 2023. PMID: 36148538
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS, Giuliano A, Fries W, Viola A, Abbruzzese A, Cappello M, Giuffrida E, Carrozza L, Privitera AC, Magnano A, Ferracane C, Scalisi G, Minissale MG, Giangreco E, Garufi S, Bertolami C, Cucinotta U, Graziano F, Casà A, Renna S, Teresi G, Rizzuto G, Mannino M, Maida M, Orlando A. Macaluso FS, et al. Among authors: giuffrida e. Inflamm Bowel Dis. 2023 Feb 1;29(2):217-221. doi: 10.1093/ibd/izac064. Inflamm Bowel Dis. 2023. PMID: 35385102 Free PMC article.
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy.
Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, Bezzio C, Bodini G, Mocciaro F, Privitera AC, Simondi D, Giuffrida E, D'Incà R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Vitello A, et al. Among authors: giuffrida e. Dig Liver Dis. 2022 Mar;54(3):352-357. doi: 10.1016/j.dld.2021.08.020. Epub 2021 Sep 17. Dig Liver Dis. 2022. PMID: 34538764
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases.
Viola A, Muscianisi M, Macaluso FS, Ventimiglia M, Cappello M, Privitera AC, Magnano A, Pluchino D, Magrì G, Ferracane C, Mocciaro F, Garufi S, Giuffrida E, Costantino G, Fiocco G, Grova M, Guida L, Alibrandi A, Orlando A, Fries W; “Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)”. Viola A, et al. Among authors: giuffrida e. JGH Open. 2021 Feb 2;5(3):364-370. doi: 10.1002/jgh3.12502. eCollection 2021 Mar. JGH Open. 2021. PMID: 33732883 Free PMC article.
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Macaluso FS, Fries W, Viola A, Costantino G, Muscianisi M, Cappello M, Guida L, Giuffrida E, Magnano A, Pluchino D, Ferracane C, Magrì G, Di Mitri R, Mocciaro F, Privitera AC, Camilleri S, Garufi S, Renna S, Casà A, Scrivo B, Ventimiglia M, Orlando A. Macaluso FS, et al. Among authors: giuffrida e. Expert Opin Biol Ther. 2020 Nov;20(11):1381-1384. doi: 10.1080/14712598.2020.1830057. Epub 2020 Oct 9. Expert Opin Biol Ther. 2020. PMID: 32981373
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A. Macaluso FS, et al. Among authors: giuffrida e. Inflamm Bowel Dis. 2021 Jan 19;27(2):182-189. doi: 10.1093/ibd/izaa036. Inflamm Bowel Dis. 2021. PMID: 32083291
Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.
Macaluso FS, Cappello M, Giuffrida E, Fries W, Centritto A, Privitera AC, Inserra G, Vassallo R, Magnano A, Vinci E, Garufi S, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: giuffrida e. Aliment Pharmacol Ther. 2019 Jan;49(2):234-236. doi: 10.1111/apt.15071. Aliment Pharmacol Ther. 2019. PMID: 30589969 No abstract available.
21 results